Forward Osmosis Wastewater (FO-MBR) Patent Landscape
The FO-MBR patent field is moderately concentrated, with Porifera Inc holding a commanding lead and the United States as the dominant filing jurisdiction. The field is still expanding on a multi-year basis, though annual volume has eased from its 2022 peak and the most recent years are further understated by publication lag.
Porifera Inc leads a compact but growing FO-MBR field
Porifera Inc sits at the top of the applicant ranking with 21 patent records, more than twice the count of its nearest rival, National University of Singapore, which holds 9 patent records. The top five filers together account for 44% of the combined total across the hundred largest filers, signalling moderate-to-high concentration for a field of this size.
A clear tier gap separates Porifera Inc from the rest: no other applicant exceeds 9 patent records, and the third through fifth positions — Hydration Systems, King Abdullah University of Science and Technology, and Vantive Health GmbH — each hold 4–6 patent records. Below that cluster, activity disperses across numerous academic institutions and small commercial entities.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Porifera Inc | 21 | |
| 2 | National University of Singapore | 9 | |
| 3 | Hydration Systems | 6 | |
| 4 | KING ABDULLAH UNIV OF SCI & TECH | 6 | |
| 5 | Vantive Health GmbH | 4 | |
| 6 | Vantive US Healthcare LLC | 4 | |
| 7 | Water Conservation Technology International Inc | 3 | |
| 8 | Jiangnan University | 3 | |
| 9 | Swing Corp | 2 | |
| 10 | UWM Research Foundation Inc | 2 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Baowu Water Technology Co Ltd | 2 | |
| 12 | Istanbul Technical University | 2 | |
| 13 | Baxter Healthcare SA | 2 | |
| 14 | Saudi Arabian Oil Company | 2 | |
| 15 | Shanghai Electric Power Environmental Engineering Co Ltd | 2 | |
| 16 | YANGALI QUINTANILLA VICTOR | 2 | |
| 17 | LINARES RODRIGO VALLADARES | 2 | |
| 18 | University of Puerto Rico | 2 | |
| 19 | Baxter International Inc | 2 | |
| 20 | Gambro Lundia AB | 2 |
Porifera Inc’s dominance, combined with a strong US filing position, suggests a commercial-grade IP moat anchored in membrane separation and water-treatment process claims. Academic entrants such as National University of Singapore and King Abdullah University of Science and Technology indicate that fundamental research activity continues to feed the pipeline.
The most recent 18–24 months of filing data are subject to publication lag and will be revised upward as pending applications are published; figures for 2024–2025 should be treated as lower-bound estimates. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Multi-year growth with a 2022 peak and a membrane-dominated technology mix
The annual filing trend and IPC composition together reveal a field that expanded materially over the review window and remains anchored in two closely related technical branches, with a long tail of adjacent classes that are sparsely occupied.
Annual filing trend
Annual filings rose from 5 in 2017 to a peak of 8 in 2022, then eased to 6 in 2023; the 2024 figure of 2 and the 2025 figure of 6 are both subject to upward revision as publication lag clears. The recent three-year window is up 33% versus the prior three-year window, confirming net multi-year growth despite the post-2022 moderation.
↗ Hover for values · click a bar to ask EurekaTechnology composition
C02F (Water and wastewater treatment) and B01D (Separation processes, including filtration and membrane technology) together account for the overwhelming majority of patent records, underscoring that the core of the field is membrane-driven water processing. A61M (Devices for body fluids) is the only other branch with a visible share, reflecting medical dialysis applications of osmotic membrane technology; all remaining branches each represent only a handful of records.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Apparatus, System, and Method for Forward Osmosis …
An apparatus, system, and method for desalinating water is presented. The invention relates to recovery of water from impaired water sources by using FO and seawater as draw solution (DS). The seawater becomes diluted over time and can be easily desalinated at very low pressures. Thus, a device consumes less energy when recovering water. The apparatus… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Apparatus, System, and Method for Forward Osmosis … | 58 |
| 2 | Use of novel draw solutes and combinations thereof… | 38 |
| 3 | Forward osmosis with an organic osmolyte for cooli… | 38 |
| 4 | 高盐度高有机物浓度废水的正渗透处理方法 | 32 |
| 5 | Composite membranes comprising a sulfonated polyar… | 27 |
| 6 | Dual-layer hollow fibers with enhanced flux as for… | 26 |
| 7 | Low energy forward osmosis membrane water processi… | 24 |
| 8 | Water purification systems and methods having pres… | 21 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the FO-MBR patent structure means for R&D strategy
The combination of a clear leader, growing multi-year activity, and a narrow technology core creates both defined competition risks and exploitable gaps for new entrants and challengers.
Growth stage — expanding on a multi-year basis, eased from 2022 peak
The lifecycle evidence places FO-MBR in a Growth stage: the recent three-year filing window is up 33% versus the prior three-year window. Annual volume peaked in 2022 at 8 records and has since moderated, but the multi-year trajectory remains positive. Publication lag means the true 2024–2025 volumes are understated. This profile is consistent with a technology that has cleared proof-of-concept but has not yet reached broad commercial saturation.
Growth stageModerate-to-high concentration anchored by a single commercial leader
Porifera Inc’s 21 patent records represent a position nearly 2.3× larger than the next-ranked applicant. The top five filers hold 44% of the hundred largest filers’ combined total, a level of concentration that creates meaningful freedom-to-operate constraints for late entrants in the core membrane-separation space. The wide gap between Porifera Inc and the rest of the field leaves room for challengers to differentiate through adjacent technical approaches rather than direct head-to-head competition.
ConcentratedMedical-device and academic co-filing partnerships are the dominant collaborative patterns
The most active co-filing pair is Baxter International Inc and Baxter Healthcare SA, which have collaborated on 6 joint patent records, reflecting a coordinated corporate IP strategy in the medical osmosis segment. National University of Singapore and BASF SE have co-filed 2 records, bridging academic membrane science and industrial chemistry. Additionally, individual inventor Yangali Quintanilla Victor and King Abdullah University of Science and Technology share 2 co-filed records, as do Li Zhenyu and King Abdullah University of Science and Technology, indicating that KAUST drives external academic collaboration in the Gulf region.
Selective collaborationUS-centric filing with emerging Chinese and PCT activity
The United States is the lead jurisdiction with 35 patent records, nearly double the combined count of the next tier. China registers 15 records and WIPO PCT filings total 11, signalling that leading applicants are beginning to build international protection. India (8 records), Europe/EPO (5), Australia, Israel, and Singapore (4 each) round out the active jurisdictions, suggesting selective multi-regional strategies rather than broad global coverage by most filers.
US-ledGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Baxter International Inc | Baxter Healthcare SA | 6 |
| National University of Singapore | BASF SE | 2 |
| YANGALI QUINTANILLA VICTOR | King Abdullah University of Science and Technology | 2 |
| LI ZHENYU | King Abdullah University of Science and Technology | 2 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Porifera Inc dominates membrane processing; Baxter entities anchor the medical osmosis segment
Two distinct competitive clusters are visible: a water-treatment cluster led by Porifera Inc and academic partners, and a medical-device cluster anchored by the Baxter/Vantive entities focusing on body-fluid management devices.
Porifera Inc
Porifera Inc holds 21 patent records, the largest position in the field by a wide margin. Its technology focus is concentrated on B01D 61 separation processes and C02F 1 water and wastewater treatment, with a secondary position in B01D 65 membrane-maintenance processes. Momentum data classifies Porifera Inc as a new entrant in the most recent period, meaning its activity in the prior filing window was negligible and its current count is built primarily from recent filings — a pattern consistent with a company still actively building its IP estate rather than defending a legacy portfolio.
patent records: 21Baxter International Inc
Baxter International Inc holds 2 patent records in its own name and, together with the closely related Baxter Healthcare SA entity (also 2 records), participates in 6 co-filed records as the field’s most active collaboration pair. The combined Baxter cluster concentrates on A61M 1 (body-fluid devices), B01D 61, and B01D 63 membrane module processes — a profile squarely in the medical dialysis application of forward osmosis, distinct from Porifera Inc’s industrial water-treatment focus. Momentum data classifies both Baxter entities as new entrants, indicating recent IP buildout in this application area.
patent records: 4 (combined entity)| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Porifera Inc | 2 | ▲ new entrant |
| Baxter International Inc | 2 | ▲ new entrant |
| Baxter Healthcare SA | 2 | ▲ new entrant |
Under-served adjacent branches in FO-MBR worth watching
Several IPC branches appear at the periphery of the current FO-MBR patent corpus with low record counts relative to the dominant water-treatment classes; these represent sparse areas where technical adjacency exists but dedicated IP coverage is thin.
C05F · Organic and waste-derived fertilisers
C05F accounts for only 2 patent records and roughly 1% of the branch distribution, yet the technical connection is plausible: forward osmosis can concentrate nutrient-laden wastewater streams (phosphorus, nitrogen) into forms suitable for fertiliser recovery, directly coupling membrane separation with circular-economy resource recovery. Hydration Systems is the only applicant currently active in this branch within the FO-MBR corpus. An entrant with expertise in agricultural water management or nutrient recovery could establish a differentiated position here with limited direct IP competition.
Search this in Eureka →C25B · Electrolytic production of compounds
C25B appears at 2 patent records and 1% share, reflecting early-stage exploration of coupling FO membranes with electrolytic processes — for example, osmotically assisted electrolysis for brine concentration or draw-solute regeneration. This pairing has engineering rationale: FO can pre-concentrate saline streams that electrolytic cells then process at lower energy cost. The branch is sparse enough that a well-scoped filing program could establish a foundational position, though the technical integration between membrane and electrochemical unit operations remains at a research stage.
Search this in Eureka →How leading FO-MBR applicants differ by technology route
Route coverage across the main technology branches in the current evidence set.
| Player | C02F 1 · Water & wastewater treatment | B01D 61 · Separation processes (filtration etc.) | C02F 103 · Water & wastewater treatment | B01D 71 · Separation processes (filtration etc.) | C02F 3 · Water & wastewater treatment |
|---|---|---|---|---|---|
| Porifera Inc | Strong · 21 | Strong · 21 | Moderate · 5 | Absent | Absent |
| National University of Singapore | Strong · 8 | Strong · 8 | Absent | Moderate · 4 | Absent |
| Baxter Healthcare SA | Absent | Strong · 6 | Absent | Strong · 4 | Absent |
| Baxter International Inc | Absent | Strong · 6 | Absent | Strong · 4 | Absent |
| YANGALI QUINTANILLA VICTOR | Strong · 3 | Strong · 3 | Strong · 2 | Absent | Absent |
Frequently asked questions
Porifera Inc leads the field with 21 patent records, well ahead of the second-ranked applicant, National University of Singapore, which holds 9 patent records. The top five filers together represent 44% of the combined total across the hundred largest filers.
The field is in a Growth lifecycle stage. The recent three-year filing window is up 33% versus the prior three-year window, confirming net multi-year expansion. Annual volume peaked at 8 records in 2022 and has moderated since; the 2024–2025 figures are further understated by publication lag and will revise upward.
The United States is the dominant jurisdiction with 35 patent records. China follows with 15 records, and WIPO PCT filings total 11. India, Europe (EPO), Australia, Israel, and Singapore each show smaller but meaningful activity, suggesting selective multi-regional protection strategies among leading filers.
C02F (Water and wastewater treatment) and B01D (Separation processes, including filtration and membrane technology) are the two dominant IPC classes and together cover the overwhelming majority of records. A61M (Devices for body fluids) is the only other branch with a visible share, reflecting medical dialysis applications.
Baxter International Inc and Baxter Healthcare SA are the most active co-filing pair with 6 joint patent records. National University of Singapore and BASF SE have co-filed 2 records. King Abdullah University of Science and Technology has co-filed 2 records each with both Yangali Quintanilla Victor and Li Zhenyu.
C05F (organic and waste-derived fertilisers) and C25B (electrolytic production of compounds) each appear in only 2 patent records, making them the sparsest branches with plausible technical connection to forward osmosis processes — nutrient recovery from concentrate streams and osmotically assisted electrolysis, respectively. Both represent early-stage observations rather than validated commercial opportunities.
Map your own position in the FO-MBR patent landscape
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.